Advertisement
Advertisement
DAWN
Day One Biopharmaceuticals, Inc. Common Stock
11.42
USDSponsored
+0.94
+9.01%
Feb 06, 16:00 UTC -5
Closed
After-Market
11.43
0.00
+0.01%
DAWN Earnings Reports
Positive Surprise Ratio
DAWN beat 11 of 18 last estimates.
61%
Next Report
Date of Next Report
May 01, 2026
Estimate for Q1 26 (Revenue/ EPS)
$51.38M
/-$0.29
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
+67.02%
/-17.14%
Day One Biopharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 03, 2026, DAWN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.17 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 48.13 million, with a --% difference. The market reacted with a +26.73% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 51.38 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Day One Biopharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Day One Biopharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Day One Biopharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 26.73%, changed from $8.94 before the earnings release to $11.33 the day after.
When is Day One Biopharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 01, 2026.
What are the forecasts for Day One Biopharmaceuticals, Inc. Common Stock's next earnings report?
Based on 8
analysts, Day One Biopharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $51.38M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement